A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

By afschroeder • March 1, 2026

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira AI, Sommerhalder D, Garrido-Laguna I, Hong DS. A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. NPJ Precis Oncol. 2026 Feb 28. doi: 10.1038/s41698-026-01340-1. Epub ahead of print. PMID: 41764244.

Tags: Hematology/Oncology, Publications

Related Posts

Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Oluwole OO, Ghobadi A, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Baer MR, Schiller[...]

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]